PRECISIONadvisor’s Director David Carr recently attended World Orphan Drug Conference 2021, and found two panels particularly insightful: “Outlook on European market access strategies for rare diseases” and “Pricing & reimbursement for rare diseases in the United States.” In case you couldn’t attend, David noted the key takeaways of each presentation.
“Outlook on European market access strategies for rare diseases”
How are market access strategies in Europe for rare diseases shifting as priorities change in the present and into the near future? Three main themes: urgency, opportunity, and collaboration, highlight how stakeholders can courageously address budget deficit, maintain innovation, and coordinate processes to ultimately provide faster patient access.
Download the PDF of key takeaways here!
“Pricing & reimbursement for rare diseases in the United States”
How have the advances of cell and gene therapies impacted the rare disease landscape? The orphan drug designation processes for rare diseases have successfully incentivized development and commercialization of treatments for high unmet, but obstacles still abound. Find out how sustainable innovation and collaboration across stakeholders can help secure the future of healthcare for these treatments.
Download the PDF of key takeaways here!